Drug developer BioCryst Pharmaceuticals (NASDAQ:BCRX) has filed its experimental influenza treatment for regulatory approval.

Durham-based BioCryst is seeking Food and Drug Administration approval on peramivir, an intravenously administered anti-viral treatment that is already approved in Japan and Korea. If approved by the FDA, BioCryst said peramivir could be ready for the 2014-2015 flu season.

Peramivir was developed under a $235 million contact awarded by the Biomedical Advanced Research and Development Authority, or BARDA. But BioCryst suspended phase III clinical trials of peramivir in late 2012 after an interim analysis showed little difference between the compound and the control group.

Earlier this year, BioCryst reached agreement with the FDA on a path for filing a new drug application for peramivir. BioCryst said the application filed with the FDA includes clinical trial results from more than 2,700 subjects treated by peramivir in 27 clinical trials.